Table 2

Characteristics of ZZ-AATD patients not receiving AAT augmentation therapy and those on augmentation therapy employed in figure 5

ZZ-AATD (-aug)ZZ-AATD (+aug)
Number of subjects115
Age, years (mean±SD)60.2±8.762.2±6.0
FEV1 (% predicted)42.5±14.735.8±8.6
FVC (% predicted)83.6±10.387.6±12.8
FEV1/FVC (% predicted)42.02±9.433.6±10.9
DLCO (% predicted)43.3±14.439.2±16.4
  • AAT, alpha-1 antitrypsin; AATD, AAT deficiency; +aug, receiving augmentation therapy; -aug, no augmentation therapy; BMI, body mass index; DLCO, Diffusion capacity for carbon monoxide; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity.